The Danish pharmaceutical company LEO Pharma has acquired a prescription dermatology portfolio from German Bayer. This is the second-largest acquisition that LEO Pharma has ever made.
The portfolio includes treatments for acne, fungal skin infections, rosacea and topical steroids. By this transaction, LEO Pharma acquires the global product rights, except for Afghanistan and Pakistan. In 2017, the products generated sales of DKK 2.1bn.
The acquisition strengthens LEO Pharma’s existing business worldwide, allowing the company to reach critical mass in several markets.
The transaction also includes the transfer of 450 employees in sales and marketing functions in 14 countries and a factory in Italy.
The transaction does not include Bayer’s over-the-counter dermatology portfolio.
Accura advised LEO Pharma.